Erleada

Active Substance

 apalutamide

Holder

 Janssen-Cilag NV

Status

Closed

Indication

in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Public documents

Approbation

Information for the patient

Informed consent

Last update

31/08/2021
Last updated on